MRVI on Nasdaq

Maravai LifeSciences Holdings, Inc.

A life sciences company.1

Price unavailable

Last updated Oct 19, 2026.

Overview

$185.7MRevenue, fiscal 20253
-$130.8MNet income, fiscal 20253

Compare with Stoke Therapeutics, Inc., LifeVantage or Rhythm (United states), or pick any stock.

  • TickerMRVI on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Websitewww.maravai.com
  • Incorporated inDE4
  • Business address10770 Wateridge Circle Suite 200, San Diego, Ca 921214
  • Filer categoryAccelerated filer4

See how the biggest companies compare on our leaderboards

Maravai LifeSciences Holdings, Inc. (also referred to in this document as “Maravai,” “we,” “us,” “our” or “the Company”) is a life sciences company providing critical products and services to enable the development of drugs, therapeutics, vaccines, and diagnostics, and support research on human disease. Our customers include biopharmaceutical companies, emerging biotech firms, life science research organizations, academic research institutions and diagnostics companies.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

18.3%Gross margin3
-115.9%Operating margin3
-70.4%Net margin3
-28.3%Revenue growth, 20253
-61.6%Return on equity3
1.35×Debt to equity3
-$70.7MFree cash flow3

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

TriLink brought in 64% of the revenue Maravai LifeSciences Holdings, Inc. broke down this way in fiscal 2025.

  1. TriLink$119.8M364%down 39% from 2024
  2. Cygnus$66.0M336%up 5% from 2024
Business segments by year
Business segments202320242025
TriLink$224.8M$196.3M$119.8M
Cygnus$64.2M$62.8M$66.0M

Regions

North America brought in 38% of the revenue Maravai LifeSciences Holdings, Inc. broke down this way in fiscal 2025.

  1. North America$112.4M338%down 12% from 2024
  2. United States$110.9M337%down 10% from 2024
  3. Asia Pacific$41.5M314%down 54% from 2024
  4. EMEA$30.9M310%down 26% from 2024
  5. Latin And Central America$971.0K30%up 47% from 2024
Regions by year
Regions202320242025
North America$141.1M$127.1M$112.4M
United States$137.9M$123.7M$110.9M
Asia Pacific$97.4M$89.4M$41.5M
EMEA$49.9M$42.1M$30.9M
Latin And Central America$527.0K$662.0K$971.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue48¢$151.8M
  • Research and development5¢$17.4M
  • Selling, general and admin46¢$145.1M
  • Income tax1¢$4.2M

Out of $185.7M in revenue.3 The company lost money this year.

Financial statements

Revenue67893$185.7M in 2025+30% since 2019
0$250.0M$500.0M$750.0M$1.0B2019: $143.1M$143.1M20192020: $284.1M$284.1M2020+98%2021: $799.2M$799.2M2021+181%2022: $883.0M$883.0M2022+10%2023: $288.9M$288.9M2023−67%2024: $259.2M$259.2M2024−10%2025: $185.7M$185.7M2025−28%
Gross profit3$34.0M in 2025−76% since 2023
0$50.0M$100.0M$150.0M2023: $140.2M$140.2M20232024: $108.3M$108.3M2024−23%2025: $34.0M$34.0M2025−69%
Operating income67893-$215.3M in 2025
-$250.0M0$250.0M$500.0M$750.0M2019: $24.0M$24.0M20192020: $119.9M$119.9M2020+400%2021: $554.6M$554.6M2021+363%2022: $574.2M$574.2M2022+4%2023: -$31.6M-$31.6M20232024: -$235.6M-$235.6M2024+644%2025: -$215.3M-$215.3M2025−9%
Net income67893-$130.8M in 2025+2826% since 2019
-$200.0M-$100.0M0$100.0M$200.0M$300.0M2019: -$4.5M-$4.5M20192020: $89.0M$89.0M20202021: $182.0M$182.0M2021+105%2022: $220.2M$220.2M2022+21%2023: -$119.0M-$119.0M20232024: -$144.8M-$144.8M2024+22%2025: -$130.8M-$130.8M2025−10%

Every line of the income statement as filed: the last 3 fiscal years, latest first.3

Period ending2025-12-312024-12-312023-12-31
Revenue$185.7M$259.2M$288.9M
Cost of revenue$151.8M$150.9M$148.7M
Gross profit$34.0M$108.3M$140.2M
Selling, general and administrative$145.1M$161.8M$151.4M
Research and development$17.4M$19.2M$17.3M
Change in estimated fair value of contingent consideration$200.0K-$2.0M-$3.3M
Impairment of goodwill and long-lived assets$68.7M$166.2M$0
Restructuring$17.8M-$1.2M$6.5M
Total operating expenses$249.3M$343.9M$171.8M
Loss from operations-$215.3M-$235.6M-$31.6M
Interest expense-$27.0M-$47.7M-$45.9M
Interest income$11.4M$27.4M$27.7M
Loss on extinguishment of debt$0-$3.2M$0
Change in payable to related parties pursuant to the Tax Receivable Agreement$0-$40.0K$668.9M
Other expense-$4.2M-$2.3M-$1.3M
(Loss) income before income taxes-$235.0M-$261.5M$617.7M
Income tax (benefit) expense-$4.2M-$1.9M$756.1M
Net loss-$230.8M-$259.6M-$138.4M
Net loss attributable to non-controlling interests-$100.0M-$114.8M-$19.3M
Net loss attributable to Maravai LifeSciences Holdings, Inc.-$130.8M-$144.8M-$119.0M
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - basic (in usd per share)-$0.90-$1.05-$0.90
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc. - diluted (in usd per share)-$0.90-$1.05-$0.90
Weighted average Class A common shares outstandingbasic (in shares)144.4M shares137.9M shares131.9M shares
Weighted average Class A common shares outstanding - diluted (in shares)144.4M shares137.9M shares131.9M shares

Compare Maravai LifeSciences Holdings, Inc. with another company

Leadership

Who has led Maravai LifeSciences Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Carl Hull2020–2023
  2. Bernd Brust2025–now

President

  1. Eric Tardif2020

Chief financial officer

  1. Kevin Herde2020–2025
  2. Rajesh Asarpota2025–now
2025
Board members and other officers (22)

Timeline

  1. Jun 10, 2025New chief executive Bernd Brust becomes CEO14
  2. Nov 19, 2020New chief executive Carl Hull becomes CEO15

Filings

324 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 182 insider forms, 45 large holders, 29 other. The latest 20:

  1. Oct 9, 20264 EDGAR
  2. Oct 1, 20264 EDGAR
  3. Sep 29, 2026SCHEDULE 13G EDGAR
  4. Sep 9, 20264 EDGAR
  5. Sep 1, 20264 EDGAR
  6. Aug 13, 2026SCHEDULE 13G/A EDGAR
  7. Aug 11, 20264 EDGAR
  8. Aug 7, 202610-Q EDGAR
  9. Aug 6, 20268-K EDGAR
  10. Aug 3, 20264 EDGAR
  11. Jul 10, 20264 EDGAR
  12. Jul 1, 20264 EDGAR
  13. Jun 29, 2026SCHEDULE 13G EDGAR
  14. Jun 23, 2026SCHEDULE 13G EDGAR
  15. Jun 10, 2026144 EDGAR
  16. Jun 10, 20264 EDGAR
  17. Jun 10, 20264 EDGAR
  18. Jun 10, 20264 EDGAR
  19. Jun 9, 2026144 EDGAR
  20. Jun 3, 20268-K EDGAR

The 324 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 7 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 10, 2026ORESHACK KURTGeneral CounselSale25,000$5.10$127.5KForm 4
Jun 9, 2026ORESHACK KURTGeneral CounselSale25,000$5.06$126.5KForm 4
Dec 8, 2025LUCIER GREGORY TDirectorBuy48,528$3.67$178.1KForm 4
Dec 5, 2025LUCIER GREGORY TDirectorBuy51,472$3.70$190.4KForm 4
Nov 13, 2025Brust BerndChief Executive OfficerBuy216,212$3.25$702.7KForm 4
Nov 12, 2025Brust BerndChief Executive OfficerBuy93,358$3.21$299.7KForm 4
Nov 11, 2025Brust BerndChief Executive OfficerBuy157,201$3.24$509.3KForm 4
Jan 31, 2025ORESHACK KURTGeneral CounselSale25,000$5.03$125.8KForm 4
Nov 12, 2024DeFord John ADirectorBuy17,500$5.75$100.6KForm 4
Nov 11, 2024HULL CARLSee RemarksBuy175,000$5.64$987.0KForm 4
May 28, 2024MARAVAI LIFE SCIENCES HOLDINGS, LLCDirectorSale9,940,974$9.82$97.6MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Gtcr LLC20,150,005$125.7M3.2%No change
BlackRock, Inc.9,970,780$62.2M0.0%+625,512
Braidwell LP8,702,921$54.3M2.1%−1,537,243
First Eagle Investment Management, LLC7,342,574$45.8M0.0%+4,818,238
12 West Capital Management LP7,060,195$44.1M8.2%−200,000
Millennium Management LLC6,508,220$40.6M0.0%+4,858,730
Vanguard Capital Management LLC5,283,665$33.0M0.0%−166,037
Ophir Asset Management Pty Ltd4,826,698$30.1M2.5%New
Renaissance Technologies LLC4,606,491$28.7M0.0%+341,802
Deutsche Bank Ag\4,304,927$26.9M0.0%+3,446,672
Geode Capital Management, LLC3,130,258$19.5M0.0%+301,663
State Street Corp2,901,706$18.1M0.0%+472,989
Nuveen, LLC2,857,580$17.8M0.0%+2,627,433
Jpmorgan Chase & Co2,593,559$16.6M0.0%+2,236,299
Two Sigma Investments, LP2,255,820$14.1M0.0%+675,980
Monaco Asset Management SAM2,231,026$13.9M5.2%−1,189,994
Prudential Financial Inc2,152,154$13.4M0.0%+2,133,684
Citadel Advisors LLC2,122,598$13.2M0.0%+638,279
Point72 Asset Management, L.P.2,005,579$12.5M0.0%−1,199,917
Morgan Stanley1,908,276$11.9M0.0%−1,411,049
Philosophy Capital Management LLC1,900,000$11.9M1.1%−737,117
Tudor Investment Corp Et Al1,849,079$11.5M0.0%+1,452,164
Royce & Associates LP1,808,448$11.3M0.1%No change
General American Investors Co Inc1,716,193$10.7M0.6%No change
Hillsdale Investment Management Inc.1,682,878$10.5M0.2%New

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

1 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Apr 10, 2023Daniel S. GoldmanDemocratic, HouseSale$1,001 - $15,000+137.7%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49